Patents by Inventor Alan James Mueller-Breckenridge

Alan James Mueller-Breckenridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20230257748
    Abstract: The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 17, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dennis JUL HANSEN, Souphalone LUANGSAY, Alan James MUELLER-BRECKENRIDGE, Lykke PEDERSEN, Johanna Marie POSE VICENTE
  • USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20230193263
    Abstract: The present invention relates to a SBDS inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SBDS inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SBDS and capable of reducing the level of a SBDS mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: June 22, 2023
    Inventors: Souphalone Luangsay, Alan James Mueller-Breckenridge, Lykke Pedersen, Johanna Marie Walther
  • USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20230183692
    Abstract: The present invention relates to a SEPT9 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SEPT9 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SEPT9 and capable of reducing the level of a SEPT9 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: June 15, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
  • USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20230118138
    Abstract: The present invention relates to a SCAMP3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SCAMP3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SCAMP3 and capable of reducing the level of a SCAMP3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: April 20, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
  • USE OF COPS3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20230122751
    Abstract: The present invention relates to a COPS3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of COPS3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to COPS3 and capable of reducing the level of a COPS3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: April 20, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
  • USE OF SARAF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20230120063
    Abstract: The present invention relates to a SARAF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SARAF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SARAF and capable of reducing the level of a SARAF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: April 20, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge